Haemostasis Assays

Thromboplastin L

Intended Use:

Thromboplastin L is calcified Rabbit Brain Thromboplastin Suspension used for the determination of Prothrombin Time, investigation of the extrinsic pathway and monitoring of oral anticoagulant therapy in citrated human plasma.

Main Features:

Low ISI ~ 1.1
Calcified liquid ready to use reagent
Calibrated against WHO international reference preparation
Insensitive to Heparin up to 2U/mL

APTT Si L Minus

Intended Use:

APTT Si L Minus contains phospholipid extract and a near-colloidal particle activator. It is for use in the determination of Activated Partial Thromboplastin Times (aPTT), related coagulation factor assays, pre-surgical screening and monitoring of Heparin therapy using citrated plasma. The reagent can be used on manual, semi-automated and automated methods.

Main features:

Ready to use liquid components
Silica contact activator
Insensitive to low levels of Lupus
Sensitive to Heparin
Excellent factor sensitivity

Calcium Chloride

Intended use:

0.025M Calcium Chloride for use in conjunction with Helena Biosciences Thromboplastin and APTT reagents.

Clauss Fibrinogen 35 (Imidazole)

Intended use:

Clauss Fibrinogen 35 is intended for the quantitative determination of Fibrinogen based on the Clauss method, in human citrated plasma on IL/ACL Coagulation Systems. Thrombin is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the fibrinogen concentration.

Main features:

Bovine Thrombin
35 NIH Units/mL
Specifically designed for IL/ACL Coagulation systems
Linear calibration from 0.7-7g/L on the ACL 3000 Plus instrument
Insensitive to Heparin levels up to 1 U/mL on the ACL 3000 Plus

Clauss Fibrinogen 50 (Owren’s)

Intended use:

Clauss Fibrinogen 50 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Owren’s Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Main features:

Bovine Thrombin
50 NIH Units/mL
Specifically designed for use on Helena Biosciences’ C-Series (old design) and AC-4 instruments
Linear calibration from 1.5-6.5 g/L

Clauss Fibrinogen 50 (Imidazole)

Intended use:

Clauss Fibrinogen 50 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Imidazole Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Main features:

Bovine Thrombin
50 NIH Units/mL
Specifically designed for use on Helena Biosciences’ C-Series (old design) and AC-4 instruments
Linear calibration from 1.5-6.5 g/L

Clauss Fibrinogen 100 (Owren’s)

Intended use:

Clauss Fibrinogen 100 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Owren’s Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Main features:

Bovine Thrombin
100 NIH Units/mL
Linear calibration from 1.5-6.5 g/L
Suitable for use on most manual, semi-automated and automated instruments

Clauss Fibrinogen 100 (Imidazole)

Intended use:

Clauss Fibrinogen 100 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Imidazole Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Main features:

Bovine Thrombin
100 NIH Units/mL
Linear calibration from 1.5-6.5 g/L
Suitable for use on most manual, semi-automated and automated instruments

Clauss Fibrinogen (Thrombin only)

Intended use:

Clauss Fibrinogen (Thrombin only) is intended for use in the quantitative determination of Fibrinogen in human plasma using the Clauss Method.

Main features:

Thrombin only component
Bovine Thrombin
100 NIH Units/mL

Imidazole Buffer

Intended use:

Imidazole can be used with Clauss Fibrinogen and Factor assays to dilute standards, control plasma and patient plasma for manual, semi-automated and fully automated methods.

Owren’s Buffer

Intended use:

Owren’s Buffer can be used with Clauss Fibrinogen and Factor assays to dilute standards, control plasma and patient plasma for manual, semi-automated and fully automated methods.

Kaolin Suspension

Intended use:

Kaolin Suspension is used to reconstitute Thrombin where instrument methodology indicates Kaolin reconstitution of the Thrombin reagent is required for use in Clauss Fibrinogen assays.

Thrombin Time

Intended use:

The Thrombin Time reagent is intended to give a qualitative indication of abnormal Fibrinogen levels, or the presence of interfering substances such as FDPs or Heparin. Quantitative evaluation of the possible causes of prolonged Thrombin Times should be performed as follow-up studies.

Main features:

Bovine Thrombin
10 NIH Units/mL
Multiple kit formats
Suitable for use on manual, semi-automated and fully automated methods

Thrombin Time (IL TOPS)

Intended use:

The Thrombin Time reagent is intended to give a qualitative indication of abnormal Fibrinogen levels, or the presence of interfering substances such as FDPs or Heparin on IL TOPS Coagulation Systems. Quantitative evaluation of the possible causes of prolonged Thrombin Times should be performed as follow-up studies.

Main features:

Bovine Thrombin
10 NIH Units/mL
Suitable for use on IL TOPS

Platelet Agonists

Intended use:

For use in platelet aggregation studies to confirm specific platelet disorders.

Main features:

Full agonist panel available
Suitable for use with any Platelet Aggregometer
High stock concentrations allow for high and low dose dilutions recommended by CLSI guidelines

Ristocetin Cofactor Kit

Intended use:

The Ristocetin Cofactor Kit is intended for use in the quantitative determination of von Willebrand Factor activity in citrated human plasma. It is used to measure the ability of the patients’ plasma to agglutinate formalin fixed platelets in the presence of Ristocetin.

Main features:

Gold standard method for vWD testing
High activity platelets
Complete kit format
Suitable for use with all light transmission aggregometers

Ristocetin

Intended use:

Ristocetin is used in conjunction with Lyophilised Platelets for use in the quantitative determination of von Willebrand Factor activity in plasma.

Lyophilised Platelets

Intended use:

Lyophilised Platelets are intended for use in the quantitative determination of von Willebrand Factor activity in plasma. They are used to measure the ability of a patient’s plasma to agglutinate formalin-fixed platelets in the presence of Ristocetin.

Main features:

Gold Standard method for vWD testing
High activity platelets
Suitable for use with all light transmission aggregometers
Multi kit formats

Ristocetin Cofactor Abnormal Control

Intended use:

For use as an abnormal control in the Ristocetin Cofactor Assay of human plasma.

Tris-Buffered Saline

Intended use:

For use in the dilution of standards, patient samples and controls used in conjunction with the Ristocetin Cofactor Kit.

Platelet Scale Set

Intended use:

The Platelet Scale Set is intended to be used to calibrate the Helena Biosciences AggRAM at 650nm.

Rapid and accurate D-Dimer tests

Manual and automated formats
Multi-platform
UK-made kits
Screen for DVT, PE and DIC

Free Protein S

Intended use:

The Free Protein S kit is a latex immunoassay based method for the quantitative determination of Free Protein S in human plasma. It is suitable for use on automated instruments with a 600-800nm wavelength.

Main features:

Latex based assay
No prozone effect below 500%
Liquid ready to use components

Protein S (Clot)

Intended use:

Protein S is used for the determination of functional Protein S levels in citrated human plasma using a clotting method.

Main features:

Linear calibration from 10-150%
Functional free Protein S assay
Suitable for all clot based detection methods

DRVVT Screen

Intended use:

The DRVVT Screen kit is intended for the qualitative determination of Lupus Anticoagulants “LAs” in citrated human plasma. Russell’s Viper Venom directly activates Factor X to Factor Xa in the presence of phospholipids and calcium, leading to detectable clot formation in plasma. The DRVVT Screen kit is intended to be used in conjunction with the DRVVT Confirm kit.

DRVVT Confirm

Intended use:

The DRVVT Confirm kit is designed to be used in conjunction with the DRVVT Screen test kit to discriminate between Lupus Anticoagulants, factor deficiencies (II, V or X) or other inhibitors.

If the clot time of the patient samples with the DRVVT Screen procedure are greater than 3 standard deviations above the mean of the normal range and are not corrected by mixing studies, a lupus anticoagulant may be present. Under these circumstances, samples should be re-tested using the DRVVT Confirm Reagent. The increased concentration of phospholipid in this reagent is designed to neutralise lupus anticoagulants.

PCA Ratio

Intended use:

The PCA Ratio Kit is a clot based assay used in determination of resistance to activated Protein C caused by Factor V Leiden mutation. This APTT based assay creates a clotting time ratio of PCA.APTT/APTT which determines APC resistance.

Main features:

Activates endogenous Protein C (using Protac^®)
Excellent discrimination between APC resistant and normal samples
Superior result discrimination compared to traditional APC methods
Compatible with all instrumentation capable of carrying out APTT assays
Negates Lupus and Heparin interference

Intrinsic Factor Deficient Plasmas

Intended use:

The intrinsic factor deficient plasmas are intended for the quantitative determination of specific factor activity in citrated human plasma. This one stage method requires an appropriate APTT reagent and any instrument capable of performing APTT-based factor assay testing.

Main features:

Residual factor activity < 1%
All other factor activity optimal
Human plasma
Congenital and immunodepleted plasmas available
Intrinsic factor assay linearity from 10-150%

Extrinsic Factor Deficient Plasmas

Intended use:

The extrinsic factor deficient plasmas are intended for the quantitative determination of specific factor activity in citrated human plasma. This one stage method requires an appropriate PT reagent and any instrument capable of performing PT-based factor assay testing.

Main features:

Residual factor activity < 1%
All other factor activity optimal
Human plasma
Congenital and immunodepleted plasmas available
Extrinsic factor assay linearity from 10-150%

Factor-8 and Factor-9 Deficient Plasmas

Intended Use:

Helena’s high-quality factor deficient plasmas are trusted worldwide by pharmaceutical and government customers, offering a reliable method for the quality control of haemophilia treatment products.

Main Features:

Congenitally deficient plasmas ensure presence of naturally associated proteins (for example Von Willebrand Factor)
Provides more accurate factor deficiency clotting time
Residual factor activity of less than 1%
Available guaranteed HiV and Hepatitis-negative
Long-term shelf life and stability

Antithrombin Xa

Intended use:

The Antithrombin Xa kit is a chromogenic assay intended for the quantitative determination of Antithrombin III (AT-lll) activity in human citrated plasma. This two-stage method utilises Factor Xa, added to a patient plasma dilution containing AT-lll in the presence of excess heparin and calcium. After an initial incubation period (stage 1), residual Factor Xa is determined with a Factor Xa-specific chromogenic substrate (stage 2). The residual Factor Xa activity is inversely proportional to the AT-lll concentration.

Main features:

Factor Xa assay
Insensitive to Heparin Cofactor II
Linear calibration from 7.5 – 150%
Excellent open vial stability

Protein C

Intended use:

The Protein C kit is intended for the quantitative determination of Protein C in citrated human plasma. Protein C in the patient plasma is activated by a specific fraction from the Agkistrodon Contortrix snake venom (Protac^®). The amount of activated protein C (APC) is determined by monitoring the rate of hydrolysis of a Protein C specific chromogenic substrate. The release of pNA is measured and is proportional to the Protein C level in the patient’s plasma.

Main features:

Activates endogenous Protein C
Excellent open vial stability